← All trials
NCT06678581
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2023
- Primary completion
- Dec 20, 2023
- Completion date
- Jan 11, 2024
- First posted
- Nov 7, 2024
- Last posted
- Nov 12, 2024
- Enrollment
- 70
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanton Pharma Co., Ltd.Lead sponsor
- Shanton Pharma Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.